MTOR and neuroblastoma: The same work further suggests that monotherapy consisting of PI3K/mTOR inhibition alone is ineffective in neuroblastoma that do not harbor a MYCN amplification [7], which led us to speculate that NVP-BEZ235 might be better suited as part of a targeted combination therapy.